Two Sigma Advisers
ORIC icon

Two Sigma Advisers’s Oric Pharmaceuticals ORIC Stock Holding History

Two Sigma Advisers’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,200
Closed -$62.5K – 2475
2025
Q1 		$62.5K Sell
11,200
-55,300
-83% -$484K ﹤0.01% 2303
2024
Q4 		$537K Buy
66,500
+8,300
+14% +$76.2K ﹤0.01% 1748
2024
Q3 		$597K Sell
58,200
-21,900
-27% -$217K ﹤0.01% 1628
2024
Q2 		$566K Buy
80,100
+51,000
+175% +$457K ﹤0.01% 1830
2024
Q1 		$400K Sell
29,100
-2,600
-8% -$30.9K ﹤0.01% 1957
2023
Q4 		$292K Buy
31,700
+5,200
+20% +$37.6K ﹤0.01% 2109
2023
Q3 		$160K Sell
26,500
-52,500
-66% -$430K ﹤0.01% 2136
2023
Q2 		$613K Buy
79,000
+33,100
+72% +$188K ﹤0.01% 1736
2023
Q1 		$262K Sell
45,900
-9,800
-18% -$51.2K ﹤0.01% 2190
2022
Q4 		$328K Sell
55,700
-112,586
-67% -$380K ﹤0.01% 2038
2022
Q3 		$539K Sell
168,286
-96,214
-36% -$385K ﹤0.01% 1813
2022
Q2 		$1.19M Buy
264,500
+157,000
+146% +$626K ﹤0.01% 1506
2022
Q1 		$574K Buy
+107,500
New +$968K ﹤0.01% 1913

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Two Sigma Advisers's ORIC Position: Q2 2025 in Review

Two Sigma Advisers sold out of Oric Pharmaceuticals (ORIC) in Q2 2025, closing a stake of 11,200 shares — an estimated $62.5K sold.

Two Sigma Advisers first reported a position in ORIC in Q1 2022 and held it in 13 quarters. The position peaked at $1.19M in Q2 2022. 142 funds tracked by Wall St. Rank hold ORIC as of Q2 2025.

  • Two Sigma Advisers reported no remaining Oric Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 11,200 Oric Pharmaceuticals shares in Q2 2025, an estimated $62.5K.
  • Two Sigma Advisers first reported a position in Oric Pharmaceuticals in Q1 2022 and held it in 13 quarters.
  • Two Sigma Advisers's Oric Pharmaceuticals position peaked at $1.19M in Q2 2022.
  • 142 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2025.

Based on Two Sigma Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.